BCL2 and neoplasm: There are studies, claiming that increase in bcl-2 expression can be an important marker for PSA recurrence following radical prostatectomy.[9] Previous clinical studies have suggested a poor prognosis of hormonally treated Bcl-2-positive prostate carcinomas.[14, 15] Increased bcl-2 expression during the early stage of prostate cancer is reported in 32-41%.[16] Interestingly, in our series, the rate of tumor bcl-2 staining is very low, being only 5.8%.